Department of Nursing Practice, College of Nursing, Academic Health Sciences Center, University of Central Florida, Orlando, FL.
Department of Health Sciences, College of Health Professions and Sciences, Academic Health Sciences Center, University of Central Florida, Orlando, FL.
J Am Assoc Nurse Pract. 2022 Jul 1;34(7):918-923. doi: 10.1097/JXX.0000000000000729.
The FDA recently approved a unique treatment regimen for management of HIV-1 infection in adults. A one-time per month injection of cabotegravir/rilpivirine can replace a current, stable antiretroviral regimen in those with virologic suppression, without history of treatment failure, or known or suspected resistance with cabotegravir or rilpivirine. A one-month oral trial should be initiated before switching to the extended-release injectable formulation. Cabotegravir/rilpivirine showed continued virologic suppression without clinically relevant changes in CD4+ cell counts. Clinicians should understand this new HIV regimen, its indications and suitability for select patients, administration and dosing, interactions, and most reported adverse events.
美国食品和药物管理局（FDA）最近批准了一种独特的治疗方案，用于治疗成人的 HIV-1 感染。对于那些病毒学抑制、无治疗失败史、无已知或疑似对卡博特韦/利匹韦林耐药的患者，每月一次的卡博特韦/利匹韦林注射可以替代当前稳定的抗逆转录病毒治疗方案。在转换为长效注射制剂之前，应先进行为期一个月的口服试验。卡博特韦/利匹韦林显示出持续的病毒学抑制，而 CD4+ 细胞计数无临床相关变化。临床医生应该了解这种新的 HIV 治疗方案，包括其适应证和对特定患者的适用性、给药和剂量、相互作用以及最常见的不良反应。
